Three‐year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus‐eluting stent in routine PCI in patients with diabetes mellitus—AIDA sub‐study

BACKGROUND: In this prespecified AIDA‐trial sub‐study we investigate the clinical performance of absorb bioresorbable vascular scaffold (BVS) compared to Xience everolimus‐eluting stent (EES) in routine percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) at complete 3‐ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerkmeijer, Laura S.M., Tijssen, Ruben Y.G., Hofma, Sjoerd H., van der Schaaf, Rene J., Arkenbout, E. Karin, Weevers, Auke P.J.D., Kraak, Robin P., Onuma, Yoshinobu, Serruys, Patrick W., Piek, Jan J., Tijssen, Jan G.P., Henriques, Jose P.S., de Winter, Robbert J., Wykrzykowska, Joanna J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Coronary Artery Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518754/
https://www.ncbi.nlm.nih.gov/pubmed/33118696
http://dx.doi.org/10.1002/ccd.29329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518754/
https://www.ncbi.nlm.nih.gov/pubmed/33118696
http://dx.doi.org/10.1002/ccd.29329

Ejemplares similares